Screener
Sionna Therapeutics SION Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(26,779) | $(16,482) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 6,553 | 2,094 |
| Non-cash operating lease expense | 489 | 491 |
| Amortization of discount on marketable securities | (200) | (697) |
| Depreciation expense | 154 | 159 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's stock-based comp?
- Sionna Therapeutics (SION) reported stock-based comp of $6.55M in Q1 2026.
- How has Sionna Therapeutics's stock-based comp changed year-over-year?
- Sionna Therapeutics's stock-based comp increased by 212.9% year-over-year, from $2.09M to $6.55M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Sionna Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude